Does BPC 157 Cause Cancer?

Your body already contains a repair system that is always looking for damaged tissue to fix, and BPC-157 essentially turns up the volume on that system.

The way it does that is through something called VEGFR2 upregulation, which means it increases the number of VEGF receptors on your cells and makes those cells more sensitive to the signals your body already uses to grow new blood vessels. In the original study that mapped this out, researchers working with rats that had hind limb ischemia found that BPC-157 activated a signaling chain running through VEGFR2, then through Akt, then through eNOS, and the result was measurably higher vessel density in the damaged tissue. The repair signal was amplified, blood vessels grew into the area, and the tissue recovered.

That is the mechanism behind the healing. And that same mechanism is exactly why the cancer question is worth asking seriously.

When a tumor grows past a certain size, it runs out of the oxygen and nutrients that passively diffuse from nearby blood vessels, and it stalls. To keep growing it needs its own blood supply, so it does something called angiogenesis, which is the process of recruiting new blood vessels to feed it. The signal it uses to do that is VEGF, the same molecule whose receptor BPC-157 is upregulating. This is not a coincidence or a rhetorical trick. It is literally the same pathway. And the reason several cancer drugs work by blocking VEGF is that if you cut off angiogenesis, you cut off the tumor's food supply and it cannot expand.

So the concern is straightforward. If BPC-157 makes cells more sensitive to VEGF signals, and a tumor is actively sending out VEGF signals to build its blood supply, then BPC-157 could theoretically accelerate exactly what the tumor is trying to do.

There is one piece of lab data that goes in the opposite direction, which is worth understanding carefully. A 2004 study tested BPC-157 directly on a human melanoma cell line called SK-Mel-1, and found that it reduced the fraction of cells actively dividing by up to 55% compared to controls. That is a striking number, and if it replicated it would change how we think about the risk profile entirely.

But it has not replicated. That study is a conference abstract from researchers within the same group that has produced most of the pro-BPC-157 literature, and in over twenty years no independent lab has tested it again. One unreplicated in vitro result in one cell line does not establish that BPC-157 inhibits tumor growth. It establishes that the question was raised once and then left unanswered.

The picture gets more complicated when you look at a separate signaling pathway that BPC-157 activates called FAK-paxillin. This pathway plays a role in how cells move and attach to surfaces, which is the biological machinery behind cancer cell invasion and metastasis. There is no study directly testing whether BPC-157 promotes invasion through this pathway in cancer cells, but the pathway itself is well characterized in oncology as a mechanism that aggressive tumors exploit.

What we do not have is any study testing BPC-157 in a living organism with an actual tumor. No animal tumor model, no human data, nothing that would tell us whether the theoretical pro-angiogenic concern outweighs the in vitro antiproliferative signal or vice versa. A 2025 commentary published in Pharmaceuticals reviewed the existing evidence and stated plainly that no published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. A separate narrative review in Current Reviews in Musculoskeletal Medicine the same year categorized BPC-157 as investigational, meaning the evidence base is not sufficient to draw confident clinical conclusions in either direction.

The absence of evidence that it causes cancer is not the same as evidence that it does not cause cancer. That distinction matters here more than it does in most conversations.

What this actually means practically is that the risk question depends heavily on your baseline situation. For someone with no known cancer history and no precancerous conditions, the theoretical concern exists but there is no direct evidence that using BPC-157 in that context is dangerous. The VEGFR2 upregulation is happening in a body where there may be no tumor exploiting it. For someone with active cancer, a history of cancer, or known precancerous lesions, the calculation is entirely different because the mechanism that creates the theoretical risk is directly relevant to their biology, and there is no offsetting human data to provide reassurance.

The deeper point is that BPC-157 is being used widely in contexts where the mechanism is reasonably well understood but the safety envelope is not. We know how it amplifies blood vessel growth. We do not know what it does when blood vessel growth is something you specifically do not want.

That gap between mechanism and outcome is where a lot of people get into trouble with compounds like this, and it is the reason that understanding the pathway is not the same as understanding the risk.

---

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Study conditions: Rat hind limb ischemia model and human umbilical vein endothelial cell cultures. Did not test tumor models. Finding: BPC-157 increased VEGFR2 expression and activated the VEGFR2-Akt-eNOS signaling pathway, increasing vessel density in ischemic tissue.
2. Radeljak S, Seiwerth S, et al. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14-A15 (conference abstract). Study conditions: In vitro, SK-Mel-1 human melanoma cells at 2ng and 10ng concentrations. Authored by Sikiric-affiliated researchers. Never independently replicated. Finding: BPC-157 lowered total S-phase fraction (cell division) up to 55% in SK-Mel-1 melanoma cells compared to controls.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1451. Published commentary (not original research). Finding: No published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study remains unreplicated. BPC-157 activates FAK-paxillin signaling, a known pathway in cancer cell invasion.
4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. Finding: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness